Electrophysiological evaluation of Cystic Fibrosis Conductance Transmembrane Regulator (CFTR) expression in human monocytes. by Ettorre M. et al.
  	

Electrophysiological evaluation of Cystic Fibrosis Conductance Transmem-
brane Regulator (CFTR) expression in human monocytes
Michele Ettorre, Genny Verze`, Sara Caldrer, Jan Johansson, Elisa Cal-
caterra, Baroukh Maurice Assael, Paola Melotti, Claudio Sorio, Mario Buffelli
PII: S0304-4165(14)00248-7
DOI: doi: 10.1016/j.bbagen.2014.07.010
Reference: BBAGEN 27987
To appear in: BBA - General Subjects
Received date: 7 March 2014
Revised date: 30 June 2014
Accepted date: 14 July 2014
Please cite this article as: Michele Ettorre, Genny Verze`, Sara Caldrer, Jan Johans-
son, Elisa Calcaterra, Baroukh Maurice Assael, Paola Melotti, Claudio Sorio, Mario
Buﬀelli, Electrophysiological evaluation of Cystic Fibrosis Conductance Transmembrane
Regulator (CFTR) expression in human monocytes, BBA - General Subjects (2014), doi:
10.1016/j.bbagen.2014.07.010
This is a PDF ﬁle of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its ﬁnal form. Please note that during the production process
errors may be discovered which could aﬀect the content, and all legal disclaimers that
apply to the journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 1 
Title  
Electrophysiological evaluation of Cystic Fibrosis Conductance Transmembrane Regulator (CFTR) 
expression in human monocytes. 
Michele Ettorre
*-†,1
, Genny Verzè
‡-§
, Sara Caldrer
‡
, Jan Johansson
‡
, Elisa Calcaterra
‡,§
, Baroukh 
Maurice Assael
§
, Paola Melotti
§
, Claudio Sorio
2‡
, Mario Buffelli
2*-†-¶
.  
*
Department of Neurological and Movement Sciences, Section of Physiology, University of Verona, 
Strada Le Grazie 8, 37134 Verona, Italy 
‡
Department of Pathology and Diagnostics, University of Verona, Strada Le Grazie 8, 37134 
Verona, Italy,  
§
Cystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata di Verona, Piazzale Stefani 1, 
37126, Verona, Italy  
†
Center for Biomedical Computing, University of Verona, Strada le Grazie 8, 37134 Verona, Italy 
¶
National Institute of Neuroscience, Verona, Italy 
 
1
 Correspondence author: Dr. Michele Ettorre  
Dept. of Neurological and Movement Sciences, Section of Physiology, University of Verona, Strada 
le Grazie 8, 37134 Verona, Italy. 
Tel. ++39045-8027268  Fax ++39045-8027279 
Email:michele.ettorre@gmail.com 
2
 These authors contributed equally to this work 
 
 
 
 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 2 
Abstract 
Background 
Cystic Fibrosis is caused by mutations of CFTR gene, a protein kinase A-activated anion channel, and is 
associated to an persistent and excessive chronic lung inflammation, suggesting functional alterations of 
immune cells. Leukocytes express detectable levels of CFTR but the molecule has not been fully 
characterized in these cells.  
Methods 
Freshly isolated monocytes from healthy individuals and CF patients were assessed by protein expression, 
single cell electrophysiological and membrane depolarization assays. 
Results 
We recorded chloride currents by patch clamp in healthy monocytes, after administration of a CFTR 
stimulus. Currents were sensitive to a specific blocker of the CFTR channel, CFTRinh-172 and were absent in 
CF monocytes. Next, we evaluated the effects of ex vivo exposure of monocytes from Cystic Fibrosis 
patients carrying the F508del mutation to a chemical corrector, Vertex-325. We found an increase in CFTR 
expression by confocal microscopy and a recovery of CFTR function by both patch clamp and single cell 
fluorescence analysis . 
Conclusions 
We confirm the expression of functional CFTR in human monocytes and demonstrate that blood monocytes 
can represent an adequate source of primary cells to assess new therapies and define diagnosis of CF. 
General Significance 
Tests to evaluate CFTR functional abnormalities in CF disease might greatly benefit from the availability of 
a convenient source of primary cells. This electrophysiological study promotes the use of monocytes as a 
minimally invasive tool to study and monitor CFTR function in individual patients. 
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Abbreviations: 
CF, Cystic Fibrosis; CFTR, Cystic Fibrosis Conductance Transmembrane Regulator; CFTRinh-172, 
CFTR inhibitor; F508del, deletion of phenylalanine at position 508 of the CFTR gene; ICM, 
Intestinal Current Measurement; NPD, Nasal Potential Difference; S.E., Standard Error; Vertex-
325, 4-cyclohexyloxy-2-(1-[4- (4-methoxy-benzenesulfonyl)-piperazin-1-yl]-ethyl)-quinazoline; 
WCR, Whole Cell Recording. 
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1. Introduction 
  Cystic fibrosis (CF), one of the most severe genetic diseases with recessive inheritance among 
people of caucasian origin, is caused by mutations in the gene coding for Cystic Fibrosis 
Conductance Transmembrane Regulator (CFTR) [1, 2]. CFTR mutations impact cell types and the 
corresponding tissues differently, with various lung and gastrointestinal manifestations of CF and 
associated comorbidities among affected patients [4]. Although earlier pathogenic models proposed 
most of the pulmonary complications of CF to be a direct consequence of epithelial dysfunctions 
caused by the absence of functional CFTR, more recent clinical and experimental evidence has 
suggested that a defective CFTR alters the function of cells of the immune system slowing the 
resolution of inflammation and infection [5, 6]. Di and colleagues demonstrated that CFTR is 
expressed in alveolar macrophages, in which it has a critical role in the lysosomal acidification and 
production of cytokines [7, 8]. Other authors showed that CF-affected neutrophils have a decreased 
ability to kill microorganisms [8, 9]. Del Porto observed that macrophages derived from peripheral 
blood monocytes of healthy donors express CFTR and that its dysfunction alters the bactericidal 
activity against Pseudomonas Aeruginosa [10]. Altogether the decrease of CFTR expression in 
immune cells might therefore represent a leading mechanism involved in the pathogenesis of CF 
and in the development of chronic lung inflammation. As such a better understanding of the 
expression, regulation and function of CFTR in these cells is becoming a major topic in CF 
research.  
To date a little less than  2000 mutations of the CFTR gene are known but only 23-28 have been 
related to CFTR dysfunction and consequently also to CF disease [11]. This underlines the 
importance of assays evaluating CFTR activity for diagnostic purposes. Currently CFTR function is 
tested using ex vivo (Intestinal Current Measurements, ICM) and in vivo (Nasal Potential 
Differences, NPD and Sweat test) assays [12]. The same assays can also be utilized to evaluate the 
efficacy of the recently developed therapies targeting the basic defect [3]. However the possibility 
to test the efficacy of these compounds ex vivo in a patient-specific context is becoming a major 
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goal of medical research in this field. In the last few years innovative approaches based on the 
evaluation of specific patient- derived cells have been developed [13, 14].  
Along this line we have recently demonstrated CFTR expression in human peripheral monocytes 
and proposed a functional assay to evaluate its activity [15]. 
The aim of this work was to confirm and extend our previous findings. By applying whole-cell 
recordings in voltage clamp mode we first tested CFTR activity in human monocytes from CF and 
healthy individuals and we related it to results obtained by a fluorescence probe-based membrane 
depolarization assay. Subsequently, in order to explore the potential of both techniques to evaluate 
the expression and the functional recovery of CFTR in F508del mutation carrying monocytes we 
exposed these cells ex vivo to a chemical corrector, 4-cyclohexyloxy-2-(1-[4- (4-methoxy-
benzenesulfonyl)-piperazin-1-yl]-ethyl)-quinazoline (Vertex-325) a well established compound 
capable to correct mutated CFTR processing and expression in epithelial cells [16].   
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2. Material and methods 
2.1. Subjects and purification of monocytes from whole blood 
Monocytes were obtained from 4–5 ml of fresh whole blood withdrawn from 4 non CF individuals 
(mean age 34 years, range 15–48 years; 3 males and 1 female) and 4 CF patients (mean age 34.5 
years, range 24–51 years; 2 males and 2 females, Table 1). The purification protocol was described 
previously [15]. Written informed consent was obtained as approved by the local Ethical 
Committee (Azienda ospedaliera universitaria-Verona, protocol number 24737).  
2.2. Vertex -325 treatment 
Purified monocytes from 4 homozygous CF patients carrying F508del mutation (mean age 30 years, 
range 24–37 years; 4 males, Table 2) were incubated with 4-cyclohexyloxy-2-(1-[4- (4-methoxy-
benzenesulfonyl)-piperazin-1-yl]-ethyl)-quinazoline (Vertex-325, Chemical Compound Program – 
Cystic Fibrosis Foundation, U.S.A., 10 μM) or vehicle (DMSO) at 37oC for 24 h and then 
analyzed by patch clamp and single cell fluorescence assay as described below. 
2.3. Electrophysiology 
Whole-cell recordings in voltage clamp mode were performed in monocytes 24-32 hours after 
purification [17].  All experiments were conducted at room temperature (22 – 24o C) using EPC-7 
patch clamp amplifier (HEKA Electronik GmbH, Lambrecht, Germany) and the pCLAMP 9.0 and 
CLAMPFIT 9.0 as acquisition and data analysis programs respectively (Axon Instruments, 
Burlingame, CA, USA). Patch-clamp pipettes had a resistance between 6-8 MOhms. 
The pipette solution contained (in mM): 140 N-methyl D-glucamine; 40 HCl; 100 L-glutamic acid; 
0.2 CaCl2; 2 MgCl2; 1 EGTA; 10 HEPES; and 2 ATP-Mg, pH 7.2. The bath solution contained (in 
mM): 140 N-methyl D-glucamine; 140 HCl; 2 CaCl2; 1 MgCl2; and 10 HEPES, pH 7.4. The Cl
-
 
equilibrium potential was -31 mV estimated by Nernst’s equation. Cells were maximally stimulated 
by the addition of a cAMP-activating cocktail (400 μM cAMP, 10 μM forskolin, 1 mM IBMX) to 
the pipette solution with voltage steps ranging from –100 to +100 mV for 200 msec with increments 
of 10 mV from a holding potential of -40 mV. The CFTR inhibitor CFTRinh-172 (Sigma C2992) was 
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added to the bath solution at a final concentration of 10 μM to specifically inhibit CFTR activity 
[18, 19]. The reversal potential was calculated, in the different experimental conditions (basal, 
stimulus and stimulus+inhibitor), as the x-value in which the I/V relationship intercepts the X axis. 
While the cell membrane capacitance (Cm) was determined by integration of the capacitative 
transients evoked in response  to voltage steps (±10 mV) from the holding potential of -40 mV.  
2.4. Cell membrane depolarization assay 
The potential-sensitive probe bis- (1,3-diethylthiobarbituric acid) trimethine oxonol (DiSBAC2(3), 
Life Technologies, Carlsbad, USA) was used to monitor CFTR-dependent membrane potential 
(Vm) changes in monocytes from healthy donors and CF patients as described in detail previously 
[15]. Briefly, the cells were perfused at room temperature with Cl-free solution containing 100 nM 
DiSBAC2(3). A baseline was acquired for 5 minutes before addition of a CFTR stimulus, 
consisting of a cocktail containing 500 mM 8-Br-cAMP (Sigma B5386), 10 mM Forskolin and 100 
mM 3-Isobutyl-1-methylxanthine (Sigma I7018). Data are presented as percentage of signal 
variation (ΔF) as compared to the time of addition of the stimulus, according to the equation: ΔFt = 
[(Ft-F0)/F0]*100, where Ft and F0 are the fluorescence values at time t and at the time of addition 
of the stimulus, respectively. 
2.5. Immunofluorescence 
Monocytes were purified with RosetteSep (STEMCELL Technologies Inc, Vancouver, BC, 
Canada). Purified cells were fixed for 20 minutes at room temperature in Fixation buffer 
(BioLegend, San Diego, U.S.A.). After several washes with PBS, cells were incubated 20 minutes 
in permeabilization blocking solution (0.1% (v/v) Triton®X-100 and 10% (v/v) human serum (both 
Sigma-Aldrich, Missouri, U.S.A.) in PBS) and then 60 minutes with 1 mg/mL monoclonal anti-
CFTR antibody clone 13-1 (R&D Systems, Minneapolis, U.S.A) diluted in permeabilization 
blocking solution. Excess antibodies were washed away by PBS1X-0,1% Tween and cells were 
then incubated 60 minutes with 2 mg/mL Goat anti-Mouse IgG/AF594 (Life Technologies,, 
Carlsbad, U.S.A). Nuclei were stained with 3µM DAPI ((4 ′ ,6-Diamidino-2-phenylindole 
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dihydrochloride, Sigma –Aldrich, Missouri, U.S.A.) and cover slip was added using anti-fading 
mounting medium to prevent loss of fluorescence. Cells were then analyzed with a Leica TCS-SP5 
confocal microscope (Leica Microsystem, Wetzlar, Germany). 
2.6. Statistics 
Statistical analyses were performed by Prism5 software (GraphPad Software Inc., La Jolla, U.S.A.) 
A one-way ANOVA was used to compare means of variables between groups. All pair-wise 
comparisons were performed using the Tukey’s post-hoc test. A significance threshold of P<0.05 
was set for all statistical analyses.  
3. Results 
3.1. Non CF monocytes express functional CFTR channels 
  We examined the electrophysiological properties of CFTR in freshly isolated human blood 
monocytes from healthy and CF individuals, performing whole cell recording (WCR) in voltage 
clamp configuration. We added N-methyl D-glucamine in the extracellular and in the pipette 
solutions to inhibit potassium and sodium currents in order to record only Cl
-
 currents.  
  We recorded currents during the application of a train of voltage steps to monocytes from healthy 
and CF donors in: i) basal conditions, ii) after administration of an intracellular (pipette solution) 
stimulus cocktail, composed of 400 μM cAMP, 10 μM forskolin, 1 mM IBMX and iii) after 
simultaneous administration of intracellular stimulus and CFTR inhibitor in bath solution (Fig. 1-2). 
After stimulus administration we recorded chloride currents in 15 out of 18 (83%) non CF 
monocytes (Fig. 1 panel a, Stimulus). The recorded currents were sensitive to CFTRinh-172, a specific 
blocker of the CFTR channel (Fig. 1 panel a, Stimulus+CFTR-inh). Cl
-
 currents were never 
recorded in 19 CF monocytes after cocktail stimulus exposure (Fig. 2, panel a) and CFTRinh-172, did 
not modify recorded currents in CF monocytes. The graphs in panel c of figures 1 and 2 show 
average current/voltage relationships in healthy and CF monocytes respectively and indicate no 
consistent voltage dependence. Moreover, the reversal potential of -30 mV is close to the value 
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calculated from the Nernst’s equation for a perfectly Cl- selective channel (in our experimental 
condition is -31mV). 
 To confirm our data we performed other two groups of recordings:  
1. In the same healthy monocytes (n=7) we administrated intracellular stimulus followed, after 
3 minutes, by CFTR inhibitor in bath solution that significantly reduced  the chloride current 
recorded (fig. S1). 
2. Moreover to definitively show that the recorded current is chloride dependent we changed 
the Cl
-
 concentration in the bath solution to modify the reversal potential, shifting it to more 
positive values (-10 mV) and repeated the treatment as before. We recorded a current 
sensitive to CFTR inhibitor with a reversal potential of about -10 mV, as expected for a 
chloride channel (fig. S1).  
  The log 10 current density values in basal condition were of -0.22±0.07 and -0.38±0.07 in healthy 
and CF individuals, respectively. Stimulus administration induced an increase only in healthy 
subjects (0.59±0.08 and -0.24±0.04 in healthy and CF individuals, respectively) while in the 
presence of CFTRinh-172 current density dropped in cells from healthy subjects to values similar to 
those recorded in basal conditions (-0.30±0.09 and -0.22±0.07, in stimulus and basal conditions, 
respectively: Fig.1 panel d and fig. S2) 
Monocytes from the same subjects analyzed by WCR (healthy and CF donors) were studied in 
parallel by single-cell fluorescence assay (Fig. 1-2 panel b). We observed increased single cell 
fluorescence in non-CF monocytes, but not in CF monocytes, following administration of the 
stimulus, confirming that single cell depolarization assay can detect a CFTR dependent function. 
This conclusion is supported by the results obtained by the evaluation of the consequence of CFTR 
stimulation on whole-cell Cl
-
 currents. 
3.2. Vertex-325 induces recovery of CFTR function in monocytes carrying F508del mutation. 
In order to evaluate whether monocytes could represent a suitable cell model to monitor the effect 
of drugs active on CFTR channel and to confirm the presence of a functional CFTR channel in 
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these cells, we tested the efficacy of a CFTR corrector on the most common CF mutation, the 
deletion of phenylalanine at position 508 of the CFTR gene (F508del) [20, 21]. This mutation 
causes protein misfolding and retention of the protein in the endoplasmic reticulum [22], a defect 
that can be at least partially rescued by small molecules, called ”correctors” [23]. We tested a well-
characterized corrector, Vertex-325, ex vivo in monocytes carrying the homozygous F508del 
mutation (Table 2). Monocytes from the same subject were incubated for 24h with Vertex-325 or 
with vehicle (DMSO). We then compared their response to the cocktail stimulus by WCR. In 15 of 
17 Vertex-325 exposed monocytes (88%) we observed chloride currents, significantly higher than 
those detected in DMSO exposed-monocytes (7 monocytes studied, Fig. 3 panel a). Moreover we 
found that the chloride currents in Vertex-325 treated monocytes were sensitive to CFTR inh-172 (7 
monocytes studied, Fig. 3 panel c and d). We also evaluated in parallel the Vertex-325 exposed 
monocytes to CFTR stimulus by single cell fluorescence assay. Both assays confirmed that 
exposure to Vertex-325 induced a response associated to the recovery of CFTR function (Fig 3 
panel b).  
The relation Current/Voltage recorded by WCR (fig. 3 panel c) showed a reversal potential value (-
30mV) of a selective Chloride channel and no voltage dependence identical to those observed in 
monocytes from healthy individuals. 
The log 10 current density values after stimulus administration were significantly increased in 
monocytes exposed to Vertex-325 compared to control (0.42 ± 0.03 and -0.13 ± 0.07 in Vertex-325 
and DMSO exposed monocytes respectively, fig. 3 panel d) while in presence of CFTR inh-172 the 
current density values, in Vertex-treated monocytes, dropped to values similar to those observed in 
stimulated control monocytes, DMSO treated  (-0.12 ± 0.09 and -0.13 ± 0.07, respectively, fig. 3 
panel d). 
To further support the electrophysiological data we analyzed the CFTR expression, by confocal 
microscopy analysis, in Vertex-325 exposed monocytes. Consistently with the functional data, we 
observed a higher expression level of CFTR in Vertex-325 exposed monocytes as compared to 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 11 
control (Fig. 3 panel e). CFTR expression was associated to increased protein expression and loss of 
perinuclear localization of the signal  in many cells (figure 3 panel e). 
 
4. Discussion 
CF disease typically feature an exaggerated lung inflammatory response whose mechanisms are not 
yet completely understood [5]. Therefore, the evaluation of CFTR expression and function in 
leukocytes, key players of innate immunity and inflammation, becomes crucial for the 
understanding of the role played in the pathogenesis of the disease.  
In this study we extend our previous findings by describing the electrophysiological proprierties of 
CFTR expressed in human monocytes using a patch clamp technique (WCR), a method that directly 
measure transmembrane currents specifically associated to Cl
-
 transport. Under conditions in which 
Na
+
 and K
+
 currents are abolished, Cl
-
 conductance is: 1) increased by elevation of intracellular 
cAMP, 2) voltage independent as shown from the I-V relationship, 3) time independent during 
depolarization, 4) suppressed by a specific CFTR antagonist, CFTRinh-172, 5) totally absent in 
monocytes from CF patients and 6) restored in monocytes carrying the F508del mutation from 
homozygous subjects after treatment with the specific CFTR corrector, Vertex-325. Altogether 
these results not only formally demonstrate for the first time that human blood monocytes isolated 
from healthy subjects express functional CFTR on their plasma membrane, but that this expression 
is lost in CF patients and restored after an appropriate drug treatment.  
The expression of ion channels in the cell of the immune system control their differentation and 
function. A number of electrophysiological studies have identified the expression of voltage- and 
ligand-gated K
+
, Ca
2+
, Cl
-
, H
+
 and cation channels in inflammatory cells [24, 25]. The functional 
role of these channels was investigated in monocytes and in monocyte-like cells [24, 26]. However 
there is not extensive information about the chloride channel identity and function in human blood 
monocytes. Kim et al. showed volume-sensitive Cl
-
 channels in human blood monocytes that 
regulate migration of the cells [27], Cheng-yao Shi described an acidic extracellular pH-activated, 
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outward rectifying chloride channel in monocyte-derived macrophages and human peripheral 
monocytes [28] while another work found the involvement of Chloride channels in monocyte 
chemoattractant protein1-induced migration of monocytes [29].  
Di et al., showed that in alveolar macrophages CFTR chloride channel participates in control of 
phagosomal pH, important to kill internalized microorganisms [7]. In our recent works we 
described that human peripheral monocytes express CFTR [15, 30]. Despite these findings the 
specific function of CFTR in monocytes is currently unknown even if the different membrane 
depolarization of CF monocytes in comparison with controls suggest alteration of membrane-
associated functions. Along this line bone marrow transplants between CF and non-CF mice 
suggest that these cells are inherently different and that CFTR is involved directly in myeloid cell 
function. This imply that these cells contribute to the pathophysiological phenotype of the CF lung, 
a major target of disease whose disfunction is associated to high morbidity and mortality in CF [31]. 
The biophysical and pharmacological properties of the CFTR Cl
-
 currents that we recorded in 
human monocytes were similar to those  previously recorded in different other models (e.g. voltage 
independence in their I–V relationships, and time-independent activation during depolarization) 
[32]. Currents of monocytes from healthy individuals were sensitive to CFTRinh-172, a selective 
blocker of CFTR. Monocytes from CF patients showed negligible changes in conductance under 
similar experimental conditions, as previously shown also in alveolar macrophages from CFTR-null 
mice [7]. Interestingly, peak current density measured in human monocytes showed lower values 
than those recorded by Del Porto et al. in human in vitro differentiated macrophages [10]. However 
this result is not unexpected as it is likely that different amounts of CFTR are expressed in plasma 
membrane of different cell types. Indeed, Del Porto et al. found a lower quantity of CFTR mRNA 
in blood monocytes than monocyte derived macrophages [7]. Gallin et al. described that the 
expression of different ion channels in monocytes, macrophages and related cell lines is different 
and that it changes during the course of cell maturation, differentiation or activation [24]. Moreover, 
different cell culture conditions may affect CFTR expression level, which also may vary over time. 
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Brochiero et al. showed a 60% CFTR expression level reduction in cultures of pulmonary 
epithelium after 24h that was then significantly increased on day 4 [33].  
Another study showed a cell cycle-dependent CFTR expression in fresh B-lymphocytes and in B- 
and T-lymphocyte cell lines. In particular they found low chloride permeability in G0 phase and a 
high permeability in G1-S and this was related to different CFTR expression levels [34]. Under our 
experimental conditions, 24-32 hours after purification, monocytes were in G0 phase as 
demonstrated by the lack of staining with the cell cycle-related antigen Ki67 (data not shown). We 
observed that 83% of recorded monocytes from healthy donors were sensitive to CFTR-stimulus 
administration. Moreover, in our former work, we showed CFTR membrane expression in 
monocytes 24 hours after preparation[15]. The readily detectable expression of CFTR in monocytes 
during G0 phase compared to lymphocytes might be due to different functions that CFTR is 
expected to have in these two different cell types. 
Monocytes can represent a convenient source of primary cells derived from individual patients and 
we recently demonstrated their potential use as convenient source of primary cells useful to 
evaluate CFTR function to support the diagnosis of CF [35]. We now wondered whether these cells 
could be sensitive to a treatment aiming to the reconstitution of CFTR function. In the present study 
we exposed monocytes carrying F508del mutation ex vivo to Vertex-325, a well characterized 
chemical corrector able to rescue the biosynthetic defect of F508del-mutated CFTR protein and to 
increase its expression on the plasma membrane in different cell lines [36]. We focused our 
attention on the ability of patch clamp and fluorescence assay to detect the recovery of CFTR 
function in these cells. We indeed succeeded in measuring cAMP-induced chloride currents in CF 
monocytes exposed to Vertex-325 by WCR and by single cell fluorescent assay. We found that 
these currents were sensitive to CFTR antagonist, CFTRinh-172. Moreover, using confocal 
microscopy analysis, we observed an increase in CFTR expression after Vertex-325 treatment, 
consistent with electrophysiological analysis. Multiple correction mechanisms accounting for the 
rescue of F508del-CFTR have been described. Vertex-809, Vertex-325, and Corr-4a show variable 
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additive effects with the genetic revertants tested. Although other compounds are currently 
available and are being tested in clinic either alone or in combination [6, 37], Vertex-325 is taken as 
a point of reference to compare the effectiveness of new compounds and apparently acts on the 
NBD1:NBD2 dimerization interface displaying a mechanism of action distinct from that of Vertex-
809 [16, 38, 39].  
The limited success of Vertex-809 in clinical trials prompted the testing of combination therapies to 
achieve complementary rescue by distinct mechanisms of actions and full F508del-CFTR 
correction, so as to reach the functional CFTR threshold necessary to avoid CF. It is also known 
that some CFTR correctors act only on cells expressing recombinant, but not native, CFTR [40]. 
This highlights the importance to confirm activity of any experimental compound in primary cells 
before moving to animal and human studies.  
Another critical point in Cystic Fibrosis is related to the diagnosis of disease when non conventional 
CFTR mutations variants are detected. Recent guidelines for CF diagnosis require genetic test and 
sweat test, but they are not always sufficient to diagnose CF or CFTR related disorders given the 
presence of a little less than 2000 different mutations, some of which of uncertain clinical 
significance [41, 42]. Intestinal current measurement (ICM) and nasal potential difference (NPD), 
evaluating currents and potential differences respectively, directly on epithelial cells of individuals 
are currently used in specialized clinics even if the issue of standardization is still matter of debate 
[43-45]. Monocytes represent easily accessible and relatively abundant cells while alternative 
sources of primary cells are scarce (nasal epithelium), more difficult to collect (rectal or colon 
epithelium) or virtually impossibile to collect in a meaningful number of patients (lower airways). 
As such, monocytes may represent a valuable cell model for multiple tasks in both basic and 
applied science related to CF. Along this line we recently proposed a single cell fluorescence assay 
as a new test to evaluate CFTR function in blood monocytes and showed that their results were 
overlapping with those obtained by NPD measurements in the same CF subjects [15, 35]. 
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In the present work we have strenghtened and significantly expanded our previous findings as: i) we 
performed a more in-depth characterization of CFTR-dependent currents in monocytes by patch-
clamp technique, because cell depolarization assay that we proposed in our previous work is less 
specific than WCR; ii) we further support the ability of a single cell fluorescence assay to detect 
CFTR –associated activity and moreover; iii) we show the ability of both techniques to detect the 
recovery of CFTR activity in monocytes from F508del mutation carrying patients, after ex vivo 
exposure to a prototype chemical corrector like Vertex-325. The aim of our work is to provide the 
proof-of-principle that WCR in human primary leukocytes can be utilized as a suitable approach to 
evaluate CFTR function and the effect of chemical correctors. The possibility exists to improve 
manual WCR using innovative medium and high-performance patch clamp recording system that 
can greatly improve the throughput capability of a direct measure of CFTR  in these cells. Efforts 
are currently under way in our laboratories to explore this possibility.  
Altogether these results highlight fluorescence assay and patch clamp as two valuable tools to 
assess CFTR activity and further support blood monocytes as a suitable and convenient source of 
primary cells for the study of the functional consequences of various CF mutations and for the 
evaluation of the efficacy of approaches aimed to correct the basic defect in CF. 
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FIGURE LEGENDS 
Figure 1. Functional activity of CFTR in Non CF monocytes. 
Whole-cell in voltage clamp configuration and single-cell fluorescent assay of human peripheral 
monocytes of healthy subject. Panel (a): representative currents in basal conditions (Basal, upper 
registration), after administration of a stimulus cocktail (Stimulus, middle registration) in pipette 
solution and after concomitant administration of stimulus and CFTRinh-172 to the bath solution 
(Stimulus+ CFTRinh, lower registration). Currents were recorded applying 200 msec voltage steps 
from -100 to +100 mV with increments of 10 mV. Panel (b): single-cell fluorescent assay 
performed of monocytes from the same donor as those analyzed by patch clamp in panel (a). 
Percentage of fluorescence variation (∆F) is shown over time in 8-Br-cAMP/forskolin/IBMX 
stimulus condition (circles), and in basal condition (diamonds). Panel (c): average current/voltage 
relationship in basal condition (diamonds, n=10), in presence of cocktail stimulus (circles, n= 15) 
and after administration of stimulus and CFTRinh-172  (triangles, n=9). Panel (d): log10 of current 
densities calculated at +100 mV in the experimental conditions described. Data in b and c are 
means ± S.E., n indicates the number of recorded cells. **p<0.001. 
Figure 2.  Impaired CFTR function in monocytes from cystic fibrosis patients 
Whole-cell in voltage clamp configuration and single-cell fluorescent assay in human peripheral 
monocytes of CF subject. Panel (a): representative currents in basal conditions (Basal, upper 
registration), after administration of a stimulus cocktail (Stimulus, middle registration) in pipette 
solution, and after concomitant administration of stimulus and CFTRinh-172 to the bath solution 
(Stimulus+ CFTRinh, lower registration). Currents were recorded applying 200 msec voltage steps 
from -100 to +100 mV with increments of 10 mV. Panel (b): single-cell fluorescent assay 
performed of monocytes from the same patient as those analyzed by patch clamp in panel (a). 
Percentage of fluorescence variation (∆F) is shown over time in 8-Br-cAMP/forskolin/IBMX 
stimulus condition (circles), and in basal condition (diamonds). Panel (c): averaged current/voltage 
relationship in basal condition (diamonds, n=7), in presence of cocktail stimulus (circles, n=19) and 
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after administration of stimulus and CFTRinh-172 (triangles, n=8). Panel (d): log10 of current 
densities calculated at +100 mV in the experimental conditions described. Data in b and c are 
means ± S.E., n indicates the number of recorded cells. 
Figure 3. Functional recovery of CFTR in monocytes carrying F508del mutation after ex vivo 
exposure to Vertex-325 
Whole-cell recording in voltage clamp configuration and single-cell fluorescent assay in human 
peripheral monocytes from CF patients carrying F508del after ex vivo exposure toVertex-325. Panel 
(a): representative currents after administration of a stimulus cocktail (Stimulus) in pipette solution, 
in monocytes exposed to Vertex-325 or to DMSO. Currents were recorded applying 200 msec 
voltage steps from -100 to +100 mV with increments of 10 mV. Panel (b): single-cell fluorescent 
assay performed of monocytes from same individual as those analyzed by patch clamp in panel (a). 
Percentage of fluorescence variation (∆F) is shown over time in 8-Br-cAMP/forskolin/IBMX 
stimulus condition (circles), and in basal condition (diamonds). Panel (c): average current/voltage 
relationship in presence of cocktail stimulus in Vertex-325 (circles, n=17), in DMSO-treated 
monocytes (diamonds, n=7) and after stimulus and CFTRinh-172 in Vertex-325 treated monocytes 
(triangles, n= 7). Panel (d): log10 of current densities calculated at +100 mV under experimental 
conditions as described above. Panel (e) Confocal microscopy analysis performed using 
monoclonal anti-CFTR (clone 13-1) of Vertex-325 treated and control monocyte from a subject 
carrying the F508del mutation. Scale bar 10 µm (figure represents one experiment out of 2 
performed). Data in b and c are means ± S.E., n indicates the number of recorded cells. **p<0.001. 
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Table 1. CF patients enrolled in the study.  
 
Subject number Gender Genotype  Age (years) 
0948 F F508del / 4382delA 51 
0952 F F508del / 1717-1GA 24 
0961 M F508del / Q353X 32 
0986 M F508del / 1717-1GA 31 
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Table 2. CF patients whose monocytes were exposed ex vivo to Vertex-325.  
 
Subject number Gender Genotype  Age (years) 
1139 M F508del / F508del 37 
1151 M F508del / F508del 26 
1152 M F508del / F508del 35 
1200 M F508del / F508del 24 
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Highlights  
 Human non CF monocytes express a functional CFTR. 
 F508del CF monocytes recover CFTR function after ex vivo exposure to Vertex-325. 
 Monocytes as a possible support for diagnosis and drug development for CF.  
 
 
 
